Dr. Mark D. Tyson II, M.D.
Urology (Urology Physician)
13400 E Shea Blvd
Scottsdale, AZ 85259
Who else practices at this address →
Maricopa County includes primary care (13% of residents) and dental (0% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Geisel School of Medicine at Dartmouth (2010)
- Years since graduation
- 16
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 980
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Medical school: Geisel School of Medicine at Dartmouth
- 2010Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Urology Physician primary
AZ license 44610
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mayo Clinic Hospital Phoenix, AZ
Medical groups
- Mayo Clinic Arizona (1,626 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 980
- Services billed
- 5,955
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Bcg live intravesical instillation, 1 mg | 3,451 | 47 |
| Diagnostic exam of bladder and urethra using an endoscope | 477 | 311 |
| Ultrasound measurement of bladder capacity after voiding | 282 | 275 |
| Electronic assessment of bladder emptying | 160 | 159 |
| Simple bladder irrigation and/or instillation | 119 | 114 |
| Instillation of anti-cancer drug into bladder | 89 | 57 |
| New patient office or other outpatient visit, 60-74 minutes | 83 | 83 |
| Injection, ceftriaxone sodium, per 250 mg | 72 | 16 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 65 | 65 |
| Established patient office or other outpatient visit, 30-39 minutes | 61 | 52 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 6 companies reported 21 payments worth $15,208 in total to this clinician.
| Urogen Pharma, Inc. | $4,800 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $4,650 |
| Ferring Pharmaceuticals Inc. | $3,028 |
| Astellas Pharma US Inc | $2,353 |
| Janssen Biotech, Inc. | $237 |
| Immunitybio, Inc. | $140 |
| Consulting Fee | $14,400 |
|---|---|
| Food and Beverage | $808 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Urogen Pharma, Inc. May 14, 2025 | Consulting Fee | $4,800 |
| Ferring Pharmaceuticals Inc. Nov 14, 2025 | Consulting Fee ADSTILADRIN · ONCOLOGY | $2,850 |
| Astellas Pharma US Inc Dec 3, 2025 | Consulting Fee Padcev · Oncology | $2,100 |
| AstraZeneca Pharmaceuticals LP Sep 12, 2025 | Consulting Fee IMFINZI · Oncology | $1,163 |
| AstraZeneca Pharmaceuticals LP May 13, 2025 | Consulting Fee | $930 |
| AstraZeneca Pharmaceuticals LP Sep 3, 2025 | Consulting Fee | $930 |
| AstraZeneca Pharmaceuticals LP Nov 21, 2025 | Consulting Fee IMFINZI · Oncology | $698 |
| AstraZeneca Pharmaceuticals LP Dec 5, 2025 | Consulting Fee IMFINZI · Oncology | $465 |
| AstraZeneca Pharmaceuticals LP Dec 1, 2025 | Consulting Fee IMFINZI · Oncology | $233 |
| AstraZeneca Pharmaceuticals LP Jul 1, 2025 | Consulting Fee IMFINZI · Oncology | $233 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 7 companies. The companies reported $1,125,476 in research payments for these studies, mostly to the institutions running them.
- A phase 3b,open label,single arm,multi center,US study of bacillus calmette guerin bcg administered in combination with durvalumab in adult bcg naive,high risk non muscle invasive bladder cancer participants patapsco
AstraZeneca Pharmaceuticals LP - A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Ri…
Janssen Research & Development, LLC - A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasiv…
Merck Sharp & Dohme LLC - A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Ri…
Janssen Research & Development, LLC - A study of intravesical enfortumab vedotin for treatment of patients with nonmuscle invasive bladder cancer nmibc
Pfizer Inc. - ADSTILADRIN Early Utilization and Outcomes in the Real World Setting
Ferring Pharmaceuticals As · Terminated · NCT06026332 - A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Ri…
Janssen Research & Development, LLC - Blue Light Cystoscopy With Cysview Registry
Photocure Inc - Study name not reported
Organon Llc
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.